Why the study?
Does protopanaxatriol alleviate steatosis and metabolic disorders in obese mouse models?
Population
High-fat diet-induced obesity (DIO) mice, genetically obese ob/ob mice, and 3T3-L1 cells
Design
Preclinical
Authors
Loading...
Preclinical PPARγ antagonism may mitigate obesity-related steatosis in mice; leaves open human translation and safety.
Does protopanaxatriol alleviate steatosis and metabolic disorders in obese mouse models?
Protopanaxatriol acts as a novel PPARγ antagonist that alleviates obesity and hepatic steatosis in preclinical mouse models.
Zhang et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: